Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 4
2011 2
2012 12
2013 37
2014 22
2015 5
2016 1
2017 2
2018 3
2019 4
2020 3
2021 3
2022 4
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

90 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, Prajapati VH, Lio P, Hu X, Wu T, Liu J, Ladizinski B, Chu AD, Eyerich K. Blauvelt A, et al. Among authors: ladizinski b. JAMA Dermatol. 2021 Sep 1;157(9):1047-1055. doi: 10.1001/jamadermatol.2021.3023. JAMA Dermatol. 2021. PMID: 34347860 Free PMC article. Clinical Trial.
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.
Silverberg JI, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Costanzo A, Rosmarin D, Lynde C, Liu J, Gamelli A, Zeng J, Ladizinski B, Chu AD, Reich K. Silverberg JI, et al. Among authors: ladizinski b. J Allergy Clin Immunol. 2022 Mar;149(3):977-987.e14. doi: 10.1016/j.jaci.2021.07.036. Epub 2021 Aug 14. J Allergy Clin Immunol. 2022. PMID: 34403658 Free article. Clinical Trial.
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Werfel T, Zeng J, Huang X, Hu X, Hendrickson BA, Ladizinski B, Chu AD, Silverberg JI. Reich K, et al. Among authors: ladizinski b. Lancet. 2021 Jun 5;397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4. Epub 2021 May 21. Lancet. 2021. PMID: 34023009 Clinical Trial.
Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials.
Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, Jiang P, Liu J, Prajapati VH, Simpson EL, Vigna N, Teixeira HD, Barbarot S. Mendes-Bastos P, et al. Among authors: ladizinski b. J Am Acad Dermatol. 2022 Oct;87(4):784-791. doi: 10.1016/j.jaad.2022.06.012. Epub 2022 Jun 15. J Am Acad Dermatol. 2022. PMID: 35714786 Free article. Clinical Trial.
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies.
Guttman-Yassky E, Thyssen JP, Silverberg JI, Papp KA, Paller AS, Weidinger S, Chih-Ho Hong H, Hendrickson B, Dilley D, Tenorio AR, Ladizinski B, Chu AD, Liu J, Irvine AD. Guttman-Yassky E, et al. Among authors: ladizinski b. J Allergy Clin Immunol. 2023 Jan;151(1):172-181. doi: 10.1016/j.jaci.2022.09.023. Epub 2022 Oct 1. J Allergy Clin Immunol. 2023. PMID: 36195170 Free article.
Lichen amyloidosis.
Ladizinski B, Lee KC. Ladizinski B, et al. CMAJ. 2014 Apr 15;186(7):532. doi: 10.1503/cmaj.130698. Epub 2013 Oct 15. CMAJ. 2014. PMID: 24130236 Free PMC article. Review. No abstract available.
Divine skin.
Varada S, Ladizinski B, Hoenig L. Varada S, et al. Among authors: ladizinski b. JAMA Dermatol. 2014 Aug;150(8):835. doi: 10.1001/jamadermatol.2014.220. JAMA Dermatol. 2014. PMID: 25133440 No abstract available.
Seeing Red.
Ladizinski B, Federman DG. Ladizinski B, et al. J Emerg Med. 2015 Aug;49(2):192-3. doi: 10.1016/j.jemermed.2014.10.026. Epub 2015 Jun 10. J Emerg Med. 2015. PMID: 26070383 No abstract available.
Cimex "liketolickus".
Ladizinski B, Cohen YK, Elpern DJ. Ladizinski B, et al. J Emerg Med. 2014 Feb;46(2):e61-2. doi: 10.1016/j.jemermed.2013.08.059. Epub 2013 Oct 11. J Emerg Med. 2014. PMID: 24126068 No abstract available.
Infliximab-induced urticaria.
Ladizinski B, Lee KC. Ladizinski B, et al. J Emerg Med. 2014 May;46(5):691-2. doi: 10.1016/j.jemermed.2013.10.004. Epub 2014 Jan 29. J Emerg Med. 2014. PMID: 24484626 No abstract available.
90 results